Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
IRIS
BACKGROUND: If carotid artery narrowing remains asymptomatic (ie, has caused no recent stroke or other neurological symptoms), successful carotid endarterectomy (CEA) reduces stroke incidence for some years. We assessed the long-term effects of successful CEA.
METHODS: Between 1993 and 2003, 3120 asymptomatic patients from 126 centres in 30 countries were allocated equally, by blinded minimised randomisation, to immediate CEA (median delay 1 month, IQR 0·3-2·5) or to indefinite deferral of any carotid procedure, and were followed up until death or for a median among survivors of 9 years (IQR 6-11). The primary outcomes were perioperative mortality and morbidity (death or stroke within 30 days) and non-perioperative stroke. Kaplan-Meier percentages and logrank p values are from intention-to-treat analyses. This study is registered, number ISRCTN26156392.
FINDINGS: 1560 patients were allocated immediate CEA versus 1560 allocated deferral of any carotid procedure. The proportions operated on while still asymptomatic were 89·7% versus 4·8% at 1 year (and 92·1%vs 16·5% at 5 years). Perioperative risk of stroke or death within 30 days was 3·0% (95% CI 2·4-3·9; 26 non-disabling strokes plus 34 disabling or fatal perioperative events in 1979 CEAs). Excluding perioperative events and non-stroke mortality, stroke risks (immediate vs deferred CEA) were 4·1% versus 10·0% at 5 years (gain 5·9%, 95% CI 4·0-7·8) and 10·8% versus 16·9% at 10 years (gain 6·1%, 2·7-9·4); ratio of stroke incidence rates 0·54, 95% CI 0·43-0·68, p<0·0001. 62 versus 104 had a disabling or fatal stroke, and 37 versus 84 others had a non-disabling stroke. Combining perioperative events and strokes, net risks were 6·9% versus 10·9% at 5 years (gain 4·1%, 2·0-6·2) and 13·4% versus 17·9% at 10 years (gain 4·6%, 1·2-7·9). Medication was similar in both groups; throughout the study, most were on antithrombotic and antihypertensive therapy. Net benefits were significant both for those on lipid-lowering therapy and for those not, and both for men and for women up to 75 years of age at entry (although not for older patients).
INTERPRETATION: Successful CEA for asymptomatic patients younger than 75 years of age reduces 10-year stroke risks. Half this reduction is in disabling or fatal strokes. Net benefit in future patients will depend on their risks from unoperated carotid lesions (which will be reduced by medication), on future surgical risks (which might differ from those in trials), and on whether life expectancy exceeds 10 years.
FUNDING: UK Medical Research Council, BUPA Foundation, Stroke Association.
10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial.
Halliday, A;Harrison, M;Hayter, E;Kong, X;Mansfield, A;Marro, J;Pan, H;Peto, R;Potter, J;Rahimi, K;Rau, A;Robertson, S;Streifler, J;Thomas, D;Fraedrich, G;Schmidauer, C;Hölzenbein, T. H;Huk, I;Haumer, M;Kretschmer, G;Metz, V;Polterauer, P;Teufelsbauer, H;Cras, P;Hendriks, J;Lauwers, P;van Schil, P;de Souza, E. B;Emilio Dourado, M;Gurgel, G;Myrian Rocha, G;Petrov, V;Slabakov, G;Cooper, M. E;Gubitz, G;Holness, R;Howes, W;Langille, R;Legg, K;Nearing, S;MacKean, G;MacKay, M;Phillips, S. J;Sullivan, J;Wood, J;Erdelez, L;Sosa, T;Angelides, N. S;Christopoulos, G;Malikidou, A;Pesta, A;Ambler, Z;Mracek, J;Polivka, J;Rohan, V;Sevcik, P;Simaná, J;Beneš, V;Kramár, F;Kaste, M;Lepäntalo, M;Soinne, L;Cardon, J. M;Legalou, A;Gengenbach, B;Pfadenhauer, K;Wölfle, K. D;Flessenkämper, I;Klumpp, B. F;Marsch, J;Kolvenbach, R;Pfeiffer, T;Sandmann, W;Beyersdorf, F;Hetzel, A;Sarai, K;Schöllhorn, J;Spillner, G;Lutz, H. J;Böckler, D;Maeder, N;Busse, O;Grönniger, J;Haukamp, F;Balzer, K;Knoob, H. G;Roedig, G;Virreira, L;Franke, S;Moll, R;Schneider, J;Dayantas, J;Sechas, M. N;Tsiaza, S;Kiskinis, D;Apor, A;Dzinich, C;Entz, L;Hüttl, K;Jàrànyi, Z;Mogan, I;Nagy, Z;Szabo, A;Varga, D;Juhász, G;Mátyás, L;Hutchinson, M;Mehigan, D;Aladjem, Z;Harah, E;Elmakias, S;Gurvich, D;Yoffe, B;Ben Meir, H;Dagan, L;Karmeli, R;Keren, G;Shimony, A;Weller, B;Avrahami, R;Koren, A;Streifler, J. Y;Tabachnik, S;Zelikovski, A;Angiletta, D;Federico, F;Impedovo, G;Marotta, V;Pascazio, L;Regina, G;Andreoli, A;Pozzati, E;Bonardelli, S;Giulini, S. M;Guarneri, B;Caiazzo, P;Mascoli, F;Becchi, G;Masini, R;Santoro, E;Simoni, G;Ventura, M;Scarpelli, P;Spartera, C;Arena, O;Collice, M;Puttini, M;Romani, F;Santilli, I;Segramora, V;Sterzi, R;Deriu, G;Verlato, F;Cao, P. G;Cieri, E;de Rango, P;Moggi, L;Ricci, S;Antico, A;Spigonardo, F;Malferrari, G;Tusini, N;Vecchiati, E;Cavallaro, A;Kasemi, H;Marino, M;Sbarigia, E;Speziale, F;Zinicola, N;Alò, F. P;Bartolini, M;Carbonari, L;Caporelli, S;Grili Cicilioni, C;Lagalla, G;Ioannidis, G;Pagliariccio, G;Silvestrini, M;PALOMBO, DOMENICO;Peinetti, F;Adovasio, R;Chiodo Grandi, F;Mase, G;Zamolo, F;Fregonese, V;Gonano, N;Mozzon, L;Blair, R;Chuen, J;Ferrar, D;Garbowski, M;Hamilton, M. J;Holdaway, C;Muthu, S;Shakibaie, F;Vasudevan, T. M;Kroese, A;Slagsvold, C. E;Dahl, T;Johnsen, H. J;Lange, C;Myhre, H. O;Gniadek, J;Andziak, P;Elwertowski, M;Leszczynski, J;Malek, A. K;Mieszkowski, J;Noszczyk, W;Szostek, M;Toutounchi, S;Correia, C;Pereira, M. C;Akchurin, R. S;Flis, V;Miksic, K;Stirn, B;Tetickovic, E;Cairols, M;Capdevila, J. M;Iborra Ortega, E;Obach, V;Riambau, V;Vidal Barraquer, F;Vila Coll, R;Diaz Vidal, E;Iglesias Negreia, J. I;Tovar Pardo, A;Segura Iglesias, R. J;Alfageme, A. F;Barba Velez, A;Estallo Laliena, L;Garcia Monco, J. C;Rodriguez Gonzalez, L;Corominas, C;Julia, J;Lozano, P;Marti Masso, J. F;Porta, R. M;Rosendo Carrera, A;Gomez, J;Blomstrand, C;Gelin, J;Holm, J;Karlström, L;Mattsson, E;Bornhov, S;Dahlstrom, J;de Pedis, G;Jensen, S. M;Pärsson, H;Plate, G;Qvarfordt, P;Arvidsson, B;Brattström, L;Forssell, C;Potemkowski, A;Skiöldebrand, C;Stoor, P;Blomqvist, M;Calander, M;Forssell, C;Lundgren, F;Almqvist, H;Norgren, L;Norrving, B;Ribbe, E;Thörne, J;Gottsäter, A;Mätzsch, T;Nilsson, M. E;Forssell, C;Lonsson, M;Lundgren, F;Stahre, B;Norgren, L;Stenberg, B;Konrad, P;Jarl, L;Lundqvist, L;Olofsson, P;Rosfors, S;Skiöldebrand, C;Swedenborg, J;Takolander, R;Bergqvist, D;Ljungman, C;Pärsson, H;Kniemeyer, H. W;Widmer, M. K;Kuster, R;Kaiser, R;Nagel, W;Sege, D;Weder, B;de Nie, J;Doelman, J;Yilmaz, N;Buth, J;Stultiens, G;Boiten, J;Boon, A;van der Linden, F;Busman, D. C;Sinnige, H. A. W;Yo, T. I;de Borst, G. J;Eikelboom, B. C;Kappelle, L. J;Moll, F;van Reedt Dortland, R. W. H;Westra, T. E;Jaber, H;Manaa, J;Meftah, R. B;Nabil, B. R;Sraieb, T;Bateman, D;Budd, J;Horrocks, M;Kivela, M;Shaw, L;Walker, R;D'Sa, A. A. B. B;Simms, M;Baird, R;Campbell, M;Cole, S;Ferguson, I. T;Lamont, P;Mitchell, D;Sassano, A;Smith, F. C. T;Blake, K;Kirkpatrick, P. J;Martin, P;Turner, C;Clegg, J. F;Crosley, M;Hall, J;de Cossart, L;Edwards, P;Fletcher, D;Rosser, S;McCollum, P. T;Davidson, D;Levison, R;Bradbury, A. W;Chalmers, R. T. A;Dennis, M;Murie, J;Ruckley, C. V;Sandercock, P;Campbell, W. B;Frankel, T;Gardner Thorpe, C;Gutowski, N;Hardie, R;Honan, W;Niblett, P;Peters, A;Ridler, B;Thompson, J. F;Bone, I;Welch, G;Grocott, E. C;Overstall, P;Aldoori, M. I;Dafalla, B. E. A;Bryce, J;Clarke, C;McCollum, P. T;Ming, A;Wilkinson, A. R;Bamford, J;Berridge, D;Scott, J;Abbott, R. J;Naylor, R;Harris, P;Humphrey, P;Adiseshiah, M;Aukett, M;Baker, D;Bishop, C. C. R;Boutin, A;Brown, M;Burke, P;Burnand, K. G;Colchester, A;Coward, L;Davies, A. H;Espasandin, M;Giddings, A. E. B;Hamilton, G;Judge, C;Kakkos, S;McGuiness, C;Morris Vincent, P;Nicolaides, A;Padayachee, T. S;Riordan, H;Sullivan, E;Taylor, P;Thompson, M;Wolfe, J. H. N;McCollum, C. N;O'Neill, P. A;Welsh, S;Barnes, J;Cleland, P;Davis, M;Gholkar, A;Jones, R;Jaykishnam, V;Mendelow, A. D;O'Connell, J. E;Siddique, M. S. S;Stansby, G;Vivar, R;Ashley, S;Cosgrove, C;Gibson, J;Wilkins, D. C;Chant, A. D. B;Frankel, J;Shearman, C. P;Williams, J;Hall, G;Holdsworth, R;Davies, J. N;McLean, B;Woodburn, K. R;Brown, G;Curley, P;Loizou, L;Chaturvedi, S;Diaz, F;Radak, D;Todorovic, P. R;Kamugasha, D;Baxter, A;Berry, C;Burrett, J;Collins, R;Crowther, J;Davies, C;Farrell, B;Godwin, J;Gray, R;Harwood, C;Hirt, L;Hope, C;Knight, S;Lay, M;Munday, A;Murawska, A;Peto, C. G;Radley, A;Richards, S.
2010-01-01
Abstract
BACKGROUND: If carotid artery narrowing remains asymptomatic (ie, has caused no recent stroke or other neurological symptoms), successful carotid endarterectomy (CEA) reduces stroke incidence for some years. We assessed the long-term effects of successful CEA.
METHODS: Between 1993 and 2003, 3120 asymptomatic patients from 126 centres in 30 countries were allocated equally, by blinded minimised randomisation, to immediate CEA (median delay 1 month, IQR 0·3-2·5) or to indefinite deferral of any carotid procedure, and were followed up until death or for a median among survivors of 9 years (IQR 6-11). The primary outcomes were perioperative mortality and morbidity (death or stroke within 30 days) and non-perioperative stroke. Kaplan-Meier percentages and logrank p values are from intention-to-treat analyses. This study is registered, number ISRCTN26156392.
FINDINGS: 1560 patients were allocated immediate CEA versus 1560 allocated deferral of any carotid procedure. The proportions operated on while still asymptomatic were 89·7% versus 4·8% at 1 year (and 92·1%vs 16·5% at 5 years). Perioperative risk of stroke or death within 30 days was 3·0% (95% CI 2·4-3·9; 26 non-disabling strokes plus 34 disabling or fatal perioperative events in 1979 CEAs). Excluding perioperative events and non-stroke mortality, stroke risks (immediate vs deferred CEA) were 4·1% versus 10·0% at 5 years (gain 5·9%, 95% CI 4·0-7·8) and 10·8% versus 16·9% at 10 years (gain 6·1%, 2·7-9·4); ratio of stroke incidence rates 0·54, 95% CI 0·43-0·68, p<0·0001. 62 versus 104 had a disabling or fatal stroke, and 37 versus 84 others had a non-disabling stroke. Combining perioperative events and strokes, net risks were 6·9% versus 10·9% at 5 years (gain 4·1%, 2·0-6·2) and 13·4% versus 17·9% at 10 years (gain 4·6%, 1·2-7·9). Medication was similar in both groups; throughout the study, most were on antithrombotic and antihypertensive therapy. Net benefits were significant both for those on lipid-lowering therapy and for those not, and both for men and for women up to 75 years of age at entry (although not for older patients).
INTERPRETATION: Successful CEA for asymptomatic patients younger than 75 years of age reduces 10-year stroke risks. Half this reduction is in disabling or fatal strokes. Net benefit in future patients will depend on their risks from unoperated carotid lesions (which will be reduced by medication), on future surgical risks (which might differ from those in trials), and on whether life expectancy exceeds 10 years.
FUNDING: UK Medical Research Council, BUPA Foundation, Stroke Association.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/351711
Citazioni
183
768
671
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.